Keina Nozaki1, Taketo Kawai2, Tetsuya Fujimura1,3, Hotaka Matsui4, Taro Teshima4, Takahiro Oshina1, Atsuko Takahashi1, Yusuke Sato4, Daisuke Yamada4, Takeshi Azuma5, Masatoshi Hotta6, Kazuhiko Nakajima6, Hidetsugu Nakayama7, Ryogo Minamimoto6, Haruki Kume4. 1. Department of Urology, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan. 2. Department of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan. taketokawai@yahoo.co.jp. 3. Department of Urology, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke-shi, Tochigi-ken, 3290498, Japan. 4. Department of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan. 5. Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-8-29, Musashidai, Fuchu-shi, Tokyo, 1838524, Japan. 6. Department of Radiology, Division of Nuclear Medicine, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan. 7. Department of Radiation Oncology, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan.
Abstract
PURPOSE: Carbon 11-choline positron emission tomography/computed tomography (11C-choline PET/CT) and subsequent local therapy for oligometastatic prostate cancer have been reported to be effective, but their effectiveness in castration-resistant prostate cancer (CRPC) remains unclear. Here, we evaluated the findings of 11C-choline PET/CT in CRPC patients and the efficacy of local treatments in correspondence of the pathologic choline uptake. METHODS: We collected 12 cases of CRPC patients who underwent 11C-choline PET/CT between 2014 and 2016. The outcomes assessed included age, the prostate-specific antigen (PSA) value, the findings of 11C-choline PET/CT, the subsequent treatments, the PSA response following the treatments, and the progression-free survival (PFS). RESULTS: Seven of 12 cases (median PSA, 3.29 ng/mL) had local prostate cancer and/or one or two metastatic lesions detected by the choline PET/CT. These localized lesions were treated with radiotherapy or lymphadenectomy. PSA decreased in all the seven cases and median PSA response was 86% (range, 23-100%). Median PFS was 8.5 months (range, 2.8-25.3 months). The other five cases (median PSA, 7.41 ng/mL) had multiple metastases and systemic therapies were continued in those cases. CONCLUSIONS: 11C-choline PET/CT and the correspondent local treatments may play an important role in the treatment sequence of CRPC in selected patients.
PURPOSE:Carbon 11-choline positron emission tomography/computed tomography (11C-choline PET/CT) and subsequent local therapy for oligometastatic prostate cancer have been reported to be effective, but their effectiveness in castration-resistant prostate cancer (CRPC) remains unclear. Here, we evaluated the findings of 11C-choline PET/CT in CRPC patients and the efficacy of local treatments in correspondence of the pathologic choline uptake. METHODS: We collected 12 cases of CRPC patients who underwent 11C-choline PET/CT between 2014 and 2016. The outcomes assessed included age, the prostate-specific antigen (PSA) value, the findings of 11C-choline PET/CT, the subsequent treatments, the PSA response following the treatments, and the progression-free survival (PFS). RESULTS: Seven of 12 cases (median PSA, 3.29 ng/mL) had local prostate cancer and/or one or two metastatic lesions detected by the choline PET/CT. These localized lesions were treated with radiotherapy or lymphadenectomy. PSA decreased in all the seven cases and median PSA response was 86% (range, 23-100%). Median PFS was 8.5 months (range, 2.8-25.3 months). The other five cases (median PSA, 7.41 ng/mL) had multiple metastases and systemic therapies were continued in those cases. CONCLUSIONS:11C-choline PET/CT and the correspondent local treatments may play an important role in the treatment sequence of CRPC in selected patients.
Authors: Laura Evangelista; Alberto Briganti; Stefano Fanti; Stephen Joniau; Sven Reske; Riccardo Schiavina; Christian Stief; George N Thalmann; Maria Picchio Journal: Eur Urol Date: 2016-02-02 Impact factor: 20.096
Authors: M Picchio; G Berardi; A Fodor; E Busnardo; C Crivellaro; G Giovacchini; C Fiorino; M Kirienko; E Incerti; C Messa; L Gianolli; N Di Muzio Journal: Eur J Nucl Med Mol Imaging Date: 2014-03-06 Impact factor: 9.236
Authors: Piet Ost; Alberto Bossi; Karel Decaestecker; Gert De Meerleer; Gianluca Giannarini; R Jeffrey Karnes; Mack Roach; Alberto Briganti Journal: Eur Urol Date: 2014-09-17 Impact factor: 20.096
Authors: Gregor Habl; Christoph Straube; Kilian Schiller; Marciana Nona Duma; Markus Oechsner; Kerstin A Kessel; Matthias Eiber; Markus Schwaiger; Hubert Kübler; Jürgen E Gschwend; Stephanie E Combs Journal: BMC Cancer Date: 2017-05-22 Impact factor: 4.430
Authors: Noura Radwan; Ryan Phillips; Ashley Ross; Steven P Rowe; Michael A Gorin; Emmanuel S Antonarakis; Curtiland Deville; Stephen Greco; Samuel Denmeade; Channing Paller; Daniel Y Song; Maximilian Diehn; Hao Wang; Michael Carducci; Kenneth J Pienta; Martin G Pomper; Theodore L DeWeese; Adam Dicker; Mario Eisenberger; Phuoc T Tran Journal: BMC Cancer Date: 2017-06-29 Impact factor: 4.430